Introduction And Classification
- Uncommon mucocutaneous blistering disorder.
- Subdivided into two primary clinical subtypes.
- Does not progress to Stevens-Johnson syndrome.
| Subtype | Clinical Characteristics | Mucosal Involvement |
|---|---|---|
| Erythema Multiforme Minor | Affects < 10% body surface area. | Absent or limited (often single site like mouth). |
| Erythema Multiforme Major | Affects < 10% body surface area. Constitutional symptoms present. | Conspicuous involvement of $\ge$ 2 mucosal sites. Includes severe buccal erosions and hemorrhagic crusts of lips. |
Etiology And Pathogenesis
| Factor Category | Specific Triggers And Mechanisms |
|---|---|
| Viral Infections | Herpes simplex virus represents most common trigger. Herpes simplex virus labialis or genitalis implicated in 60-70% of episodes. Recurrent episodes frequently associated with sun exposure. |
| Bacterial Infections | Mycoplasma pneumoniae produces similar lesions, particularly in children and young adults. |
| Pharmacologic | Accounts for < 10% of cases. Associated agents include nonsteroidal anti-inflammatory drugs, sulfonamides, and antibiotics. |
| Genetic Predisposition | Human leukocyte antigens A33, B62, B35, DQw3, and DR53 associated with increased risk of herpes simplex virus-induced recurrent disease. |
| Pathophysiology | Host-specific, cell-mediated immune response to antigenic stimulus causes keratinocyte damage. Herpes simplex virus Pol1 gene upregulates transcription factor SP1 and inflammatory cytokines. Cytokine release contributes to epidermal cell death. |
Clinical Manifestations
Cutaneous Lesions
- Peak incidence occurs between 10 and 40 years, highest in males during second decade.
- Eruption appears abruptly and symmetrically.
- Predilection for acral parts, especially extensor upper extremities, palms, and soles.
- Face, trunk, and legs relatively spared.
- Initial morphology features red macules or urticarial plaques expanding centrifugally.
- Pathognomonic targetoid (iris or bull's-eye) papules develop within 72 hours.
- Target lesions consist of three distinct concentric rings: central dusky erythema or vesicle/bulla, intermediate pale edematous ring, and peripheral erythematous halo.
- Lesions remain fixed in place for average duration of 7 days.
- Fades within approximately 2 weeks without sequelae, though postinflammatory dyspigmentation occurs in darker skin.
- Usually asymptomatic, occasionally accompanied by burning sensation or pruritus.
Mucosal Lesions
- Predilection for vermilion border of lips and buccal mucosa.
- Other mucosal surfaces usually spared in minor variant.
- Central bullous lesions and severe ulcerations define major variant.
Histopathology
- Cleavage site occurs at subepidermal level.
- Early lesions demonstrate slight intercellular edema, rare dyskeratotic keratinocytes, and epidermal basal vacuolation.
- Upper dermis exhibits edema and perivascular lymphohistiocytic infiltrate.
- Mature lesions show lymphocytic exocytosis, intense interstitial mononuclear infiltrate, and potential full-thickness epidermal necrosis.
Differential Diagnosis
- Stevens-Johnson syndrome: Distinguished by erythematous or purpuric macules (lacking papules) starting primarily on trunk.
- Urticaria: Individual lesions fade within 24 hours, unlike fixed erythema multiforme lesions.
- Reactive infectious mucocutaneous eruption.
- Bullous pemphigoid and pemphigus vulgaris.
- Kawasaki disease.
- Cefaclor-induced serum sickness-like reaction (pruritic, transient, migratory).
Management Protocol
Supportive Measures
- Primary therapy remains entirely supportive.
- Treat underlying primary infections concurrently.
- Provide symptomatic relief using topical emollients, systemic antihistamines, and nonsteroidal anti-inflammatory drugs.
- Utilize opioids and diligent oral hygiene for severe mucosal pain management.
- Systemic corticosteroids lack controlled prospective evidence supporting routine use.
Recurrent Disease Interventions
- Initiate prophylactic oral acyclovir for 6 months for recurrent herpes simplex virus-associated disease.
- Tapering acyclovir may prompt disease recurrence, albeit milder.
- Refractory cases necessitate steroid-sparing agents including azathioprine, mycophenolate mofetil, or dapsone.